

Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients

Oct 08, 2018

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-announces-fda-filing-acceptance-siponimod-baf312-first-and-only-oral-drug-shown-delay-disability-progression-typical-spms-patients-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-announces-fda-filing-acceptance-siponimod-baf312-first-and-only-oral-drug-shown-delay-disability-progression-typical-spms-patients-0>